The Hemopurifier is a medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system.
Aethlon chairman and CEO Jim Joyce said that their goal is to provide oncologists with a device that will improve effectiveness of melanoma cancer therapies without adding drug toxicity or interaction risks and the data also provides supporting insight that the Hemopurifier has broad-spectrum activity against various forms of cancer.
Aethlon claims that the Hemopurifier was effective in capturing exosomes from the fluids of five ovarian cancer patients during in vitro studies.
Aethlon believes the Hemopurifier represents the therapeutic strategy to directly inhibit or reverse the deleterious effects associated with exosomes secreted by tumors as a survival mechanism for cancer.
